20-F: Ridgetech Completes Restructuring, Focuses on Wholesale

Ridgetech, Inc. (formerly China Jo-Jo Drugstores, Inc.) has completed a significant restructuring, divesting its retail pharmacy operations and acquiring Ridgeline International Limited to focus exclusively on its wholesale pharmaceutical distribution business.

Summary

• Ridgetech, Inc. has completed a strategic restructuring, divesting its retail pharmacy business and acquiring Ridgeline International Limited to focus on wholesale pharmaceutical distribution.
• The company's fiscal year ended March 31, 2026, saw total revenue increase by 10.2% to $132.16 million, driven by a significant rise in online platform revenue.
• Offline wholesale revenue slightly decreased by 0.8% to $117.87 million, attributed to a risk mitigation strategy of discontinuing some credit sales.
• The company reported a net loss from continuing operations of $1.25 million for the fiscal year ended March 31, 2026.
• Ridgetech has identified material weaknesses in its internal control over financial reporting, including issues with U.S. GAAP reconciliation and accounting staff experience, which are being addressed.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to the continued net loss, increased operating expenses, and identified material weaknesses in internal controls, despite revenue growth and a strategic shift towards wholesale.

Positives

• Total revenue increased by 10.2% to $132.16 million for the fiscal year ended March 31, 2026.
• Online platform revenue saw a substantial increase of 1,190.8% to $14.29 million, largely due to the full-year inclusion of Allright's revenue.
• Gross profit increased by 23.8% to $4.75 million for the fiscal year ended March 31, 2026.
• The company has a working capital of $36.66 million as of March 31, 2026.
• The company believes it has sufficient financial resources to support its operations for at least the next 12 months.

Negatives

• The company reported a net loss from continuing operations of $1.25 million for the fiscal year ended March 31, 2026.
• Offline wholesale revenue decreased by 0.8% to $117.87 million.
• Selling and marketing expenses increased by 98.2% to $3.04 million, primarily due to the acquisition of Allright.
• The company has identified material weaknesses in its internal control over financial reporting, leading to ineffective disclosure controls and procedures.
• The company's market value of listed securities (MVLS) is currently below the Nasdaq requirement of $5,000,000, posing a risk of delisting.

Risks

• Significant competition in the pharmaceutical distribution industry in China.
• Potential challenges in recovering accounts receivable from divested entities and maintaining the supply relationship with Jiuzhou Pharmacy.
• Dependence on third-party electronic platforms for online sales, whose capacity or policy changes could impact growth.
• The company's reliance on key personnel, with potential disruption if their services are lost.
• Uncertainties and changes in Chinese regulations affecting business operations, data security, and capital raising.
• Potential delisting from Nasdaq due to failure to maintain minimum bid price or market value of listed securities.
• The significant voting power held by the Chairman of the Board, potentially influencing corporate actions and creating conflicts of interest.
• Material weaknesses in internal control over financial reporting could adversely affect financial reporting and investor confidence.

Future Outlook

The company has completed a strategic restructuring to focus on its wholesale business, both online and offline. It aims to grow its wholesale operations and believes it has sufficient financial resources for at least the next 12 months. However, it faces challenges related to competition, customer concentration, regulatory changes in China, and potential delisting risks.

Management Comments

• Management concluded that disclosure controls and procedures were ineffective as of March 31, 2026, due to material weaknesses in internal control over financial reporting.
• Management believes that the remediation initiatives outlined will be sufficient to remediate the material weakness in internal control over financial reporting as the changes become operational for future years.
• The company believes that its presence on multiple platforms offers greater opportunities to distribute pharmaceutical products nationwide, and that the acquisition of Allright has strengthened its online distribution capabilities and broadened its geographic reach and customer base.

Industry Context

StockSavvy.ai notes that Ridgetech's strategic shift from retail to wholesale distribution aligns with broader trends in the Chinese pharmaceutical market, which is increasingly consolidating and focusing on efficiency. The company's acquisition of Allright is a key move to bolster its online presence, a critical channel in the evolving landscape.

Corporate Governance

Legal Proceedings

• No material, existing or pending legal proceedings against the company are known.

Related Party Transactions

• On July 16, 2026, the Company issued 100,000 Series A Preferred Shares to Mr. Lingtao Kong, Chairman of the Board, for $100.
• On January 31, 2025, the Company acquired Ridgeline International Limited by issuing 14,834 ordinary shares to Mr. Lingtao Kong.
• On January 31, 2025, the Company divested equity in Jiuxin Investment to Oakview International Limited in exchange for the surrender of 16,990 ordinary shares by Mr. Lei Liu, Ms. Li Qi, and Oakview.
• Former CEO Lei Liu and CFO Ming Zhao surrendered shares for no consideration in October and November 2024.

Stakeholder Impact

• Shareholders may experience continued share price volatility and potential dilution from future capital raises.
• The significant voting power of the Chairman of the Board could influence corporate decisions, potentially not aligning with all shareholders' interests.
• The company's ability to maintain Nasdaq listing is crucial for liquidity and investor access.
• Employees are subject to the company's ongoing efforts to improve internal controls and operational efficiency.

Next Steps

• Continue to remediate material weaknesses in internal control over financial reporting.
• Monitor and manage cybersecurity risks.
• Explore opportunities to increase Market Value of Listed Securities (MVLS) to maintain Nasdaq compliance.
• Continue to develop and expand the wholesale business, both online and offline.
• Potentially resume at-the-market offering to raise capital.

Key Dates

Recommendation

While the company has shown revenue growth and a strategic shift towards a more focused wholesale business, the continued net loss, increased operating expenses, and identified material weaknesses in internal controls present significant risks. The potential delisting from Nasdaq due to MVLS is a major concern. Therefore, a 'hold' recommendation is appropriate, pending clear evidence of improved financial performance and remediation of control deficiencies.

Keywords

Ridgetech, Pharmaceutical Wholesale, China, Online Sales, Restructuring, SEC Filing, Form 20-F, Healthcare Distribution